Janus kinase

Also found in: Acronyms, Wikipedia.

Janus kinase (JAK),

a member of a particular family (JAK) of tyrosine kinases involved in cytokine receptor signaling. Mutations in JAK3 on chromosome 19p cause autosomal recessive severe combined immunodeficiency [MIM*600173]. JAK1 and JAK2 are mapped to the short arms of chromosomes 1 and 9, respectively.
[Janus, Roman god of doorways, depicted with two faces looking in opposite directions]
Farlex Partner Medical Dictionary © Farlex 2012

Janus kinase

Any of a family of four tyrosine kinases—JAK1, JAK2, JAK3 and Tyk2—that associate with cytokine receptors. Once receptors are activated, JAKs phosphorylate STAT transcription factors, initiating the JAK-STAT signalling pathway. JAK family members share a common protein domain, a kinase domain, a regulatory pseudo -kinase domain, a SH2 domain and a FERM domain, this last of which mediates the association of JAK with other enzymes and cytokine receptors.

JAK family associations
• JAK1—Mediates signals from IFN-alpha, beta, gamma and IL2, IL6 receptors.
• JAK2—Transduces signals from single chain, IL3 receptor families and IFN-gamma receptors.
• JAK3—Associates with the IL2 receptor gamma-chain.
• Tyk2—Associates with the IFN1 and IL6, -10, -12 and -23 cytokine receptors.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases (SDC-1801) and cancers (SDC-1802).
The "Global Janus Kinase (JAK) Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
Genetic factors mediate the development of cytotoxic T cells, and it's been found that the Janus kinase (JAK) pathways may be important in the immunology of the hair loss.
Other immunomodulators, such as Janus kinase inhibitors, are being investigated in AD.
However, successful treatment of several cases of AA and its variants with oral Janus kinase (JAK) inhibitors have been reported recently.
The drug blocks enzymes in the body called the janus kinase, or JAK, that stop hair from growing.
As a result of this transaction, Aclaris acquired worldwide rights to intellectual property licensed to Vixen by Columbia University covering the use of certain Janus Kinase inhibitor compounds for the treatment of alopecia areata, androgenetic alopecia and other dermatological conditions.
Treatment with Janus kinase (JAK) inhibitor drugs in aged mice, equivalent to 80-year-old people, decreased the amounts of activin A and partially reversed the fat tissue insulin resistance that contributes to diabetes in old age.
In experiments with mouse and human hair follicles, researchers found that drugs that inhibit the Janus kinase (JAK) family of enzymes promote rapid and robust hair growth when directly applied to the skin.
GSK2586184 is a Janus kinase 1 (JAK1) inhibitor, which is developed within Galapagos's inflammation alliance withA GSK.A
Strober et al., "Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study," British Journal of Dermatology, vol.
thioredoxin), mitochondriogenesis, cell signalling [JAK (Janus kinase)/STAT (signal transducer and activator of transcription) and MAPK (mitogen-activated protein kinase) pathways] and transport were most affected.